ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Upgraded by Citigroup
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) was upgraded by investment analysts at Citigroup from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Monday, Marketbeat reports. The firm currently has a $4.00 price objective on the biopharmaceutical company’s stock. Citigroup’s price objective points to a potential […]
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) was upgraded by investment analysts at Citigroup from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Monday, Marketbeat reports. The firm currently has a $4.00 price objective on the biopharmaceutical company’s stock. Citigroup’s price objective points to a potential […]
